Evidence map›Paper›PMID 34253183›Full record

ArticleBMC neurology2021

Treatment of spasticity in children and adolescents with cerebral palsy in Northern Europe: a CP-North registry study.

Gunnar Hägglund, Sandra Julsen Hollung, Matti Ahonen, Guro L Andersen, Guðbjörg Eggertsdóttir, Mark S Gaston, Reidun Jahnsen, Ira Jeglinsky-Kankainen, Kirsten Nordbye-Nielsen, Ilaria Tresoldi and 1 more

Open access · goldAbstract read
In one paragraph

Article in BMC neurology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
4.9field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 40 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. Review
  6. The evolution of nutrition management in children with severe neurological impairment with a focus on cerebral palsy.Journal of human nutrition and dietetics : the official journal of the British Dietetic Association · 2025
    Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Selective dorsal rhizotomy in non-ambulant children with cerebral palsy: a multi-center prospective study.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2024
    Observational
  13. The state of the art in therapeutic administration of botulinum toxin in children with cerebral palsy: an integrative review.Revista paulista de pediatria : orgao oficial da Sociedade de Pediatria de Sao Paulo · 2024
    Review
  14. Article
  15. Article
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 9 institutions in 6 countries.

Gunnar HägglundDepartment of Clinical Sciences Lund, Orthopedics, Lund University, Skåne University Hospital, 221 85, Lund, Sweden. gunnar.hagglund@med.lu.se.
Sandra Julsen HollungNorwegian Quality and Surveillance Registry for Cerebral Palsy, Vestfold Hospital Trust, Tønsberg, Norway.
Matti AhonenDepartment of Pediatric Orthopedics and Traumatology, Children's Hospital, Helsinki University Hospital, University of Helsinki, Helsinki, Finland.
Guro L AndersenNorwegian Quality and Surveillance Registry for Cerebral Palsy, Vestfold Hospital Trust, Tønsberg, Norway.
Guðbjörg EggertsdóttirSLF´S Rehabilitation Center- Æfingastöðin, Reykjavík, Iceland.
Mark S GastonCerebral Palsy Integrated Pathway, Scotland. Royal Hospital for Sick Children, Edinburgh, UK.
Reidun JahnsenNorwegian Quality and Surveillance Registry for Cerebral Palsy, Oslo University Hospital and University of Oslo, Oslo, Norway.
Ira Jeglinsky-KankainenDepartment of Health and Welfare, Arcada University of Applied Sciences, Helsinki, Finland.
Kirsten Nordbye-NielsenDepartment of Children's Orthopedics, Danish Cerebral Palsy Follow-Up Program, Central Region Denmark, Danish Paediatric Orthopaedic Research Group, Aarhus University, Aarhus, Denmark.
Ilaria TresoldiDepartment of Children's Orthopedics, Danish Paediatric Orthopaedic Research Group, Aarhus University, Aarhus University Hospital, Aarhus, Denmark.
Ann I Alriksson-SchmidtDepartment of Clinical Sciences Lund, Orthopedics, Lund University, Skåne University Hospital, 221 85, Lund, Sweden.
Skåne University Hospital · SESykehuset i Vestfold · NOAarhus University Hospital · DKArcada University of Applied Sciences · FICentral Denmark Region · DKHelsinki University Hospital · FIInnovation Center Iceland · ISOslo University Hospital · NORoyal Hospital for Children · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSpasticity is present in more than 80% of the population with cerebral palsy (CP). The aim of this study was to describe and compare the use of three spasticity reducing methods; Botulinum toxin-A therapy (BTX-A), Selective dorsal rhizotomy (SDR) and Intrathecal baclofen therapy (ITB) among children and adolescents with CP in six northern European countries.

methodsThis registry-based study included population-based data in children and adolescents with CP born 2002 to 2017 and recorded in the follow-up programs for CP in Sweden, Norway, Denmark, Iceland and Scotland, and a defined cohort in Finland.

resultsA total of 8,817 individuals were included. The proportion of individuals treated with SDR and ITB was significantly different between the countries. SDR treatment ranged from 0% ( Finland and Iceland) to 3.4% (Scotland) and ITB treatment from 2.2% (Sweden) to 3.7% (Denmark and Scotland). BTX-A treatment in the lower extremities reported 2017-2018 ranged from 8.6% in Denmark to 20% in Norway (p < 0.01). Mean age for undergoing SDR ranged from 4.5 years in Norway to 7.3 years in Denmark (p < 0.01). Mean age at ITB surgery ranged from 6.3 years in Norway to 10.1 years in Finland (p < 0.01). Mean age for BTX-A treatment ranged from 7.1 years in Denmark to 10.3 years in Iceland (p < 0.01). Treatment with SDR was most common in Gross Motor Function Classification System (GMFCS) level III, ITB in level V, and BTX-A in level I. The most common muscle treated with BTX-A was the calf muscle, with the highest proportion in GMFCS level I. BTX-A treatment of hamstring and hip muscles was most common in GMFCS levels IV-V in all countries.

conclusionThere were statistically significant differences between countries regarding the proportion of children and adolescents with CP treated with the three spasticity reducing methods, mean age for treatment and treatment related to GMFCS level. This is likely due to differences in the availability of these treatment methods and/or differences in preferences of treatment methods among professionals and possibly patients across countries.

Indexed as

RegistriesAdolescentBaclofenBotulinum Toxins, Type ACerebral PalsyChildChild, PreschoolCohort StudiesEuropeHumansInjections, SpinalMaleMuscle Relaxants, CentralMuscle, SkeletalMuscle SpasticityRhizotomyBaclofenBotulinum Toxins, Type AMuscle Relaxants, CentralBaclofenBotulinum toxinCerebral palsySelective dorsal rhizotomySpasticityTreatment

Identifiers

PMID34253183
PMCPMC8274039
OpenAlexW3177684521

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.